Figure and Table | Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan

Table 1. Patients’ Characteristics and the Number of Positive Cases in Each Hospital.

From: Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan

	Total (N=10377)	Kobe university hospital (Ko) (N=2048)	anonymous X Hospital (X) (N=2000)	Hyogo Prefectural Nishinomiya Hospital (NI) (N=2010)	Hyogo Prefectural Amagasaki General Medical Center (AM) (N=2000)	Hyogo Prefecture Health Promotion Association (HE) (N=1000)	Hyogo prefectural Kobe Children’s Hospital (CH) (N=1319)
Male - no.(%)	5184 (49.9)	1045 (51)	989 (49.4)	904 (44.9)	1001 (50)	596 (59.6)	689 (52.2)
Median age - yr (range)	62 (0-99)	67 (2-96)	69 (1-95)	69 (0-99)	70 (1-97)	47 (19-82)	8 (0-19)
ECLIA positive - no.(%)	27 (0.26)	5 (0.24)	7 (0.35)	4 (0.19)	6 (0.3)	4 (0.4)	1 (0.07)
CLEIA positive (-N or -S) - no.(%)	51 (0.49)	12 (0.58)	12 (0.6)	9 (0.44)	11 (0.55)	7 (0.7)	ND
CLEIA-N positive - no.(%)	29 (0.27)	4 (0.19)	11 (0.55)	7 (0.34)	4 (0.2)	3 (0.3)	ND
CLEIA-S positive - no.(%)	39 (0.37)	12 (0.58)	6 (0.3)	7 (0.34)	10 (0.5)	4 (0.4)	ND
CLEIA-N and -S positive - no.(%)	17 (0.16)	4 (0.19)	5 (0.25)	5 (0.24)	3 (0.15)	0 (0)	ND
ECLIA and CLEIA positive - no.(%)	14 (0.13)	1 (0.05)	4 (0.2)	3 (0.15)	3 (0.15)	3 (0.3)	ND
ECLIA or CLEIA positive - no.(%)	64 (0.6)	16 (0.78)	15 (0.75)	10 (0.49)	14 (0.7)	8 (0.8)	1 (0.07)
IC positive - no.(%)	22 (0.21)	2 (0.09)	8 (0.4)	5 (0.24)	3 (0.15)	4 0.4)	0 (0)
Neutralization activity positive - no.(%)	16 (0.15)	2 (0.09)	4 (0.2)	3 (0.15)	3 (0.15)	4 (0.4)	0 (0)

» Back to article page

Table 3. Results of Antibody Tests in 64 Cases Classified Based on the Patterns of ECLIA 2, CLEIA-N, and CLEIA-S.

From: Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan

	All (N=10377)	ECLIA or CLEIA positive (N=64)		Both positive (N=14)			Either positive (N=50)
			ECLIA	+	+	+	－	+	－	－	+
			CLEIA-N	+	+	－	+	－	+	－	ND
			CLEIA-S	+	－	+	+	－	－	+	ND
				(N=9)	(N=3)	(N=2)	(N=8)	(N=12)	(N=9)	(N=20)	(N=1)
Male - no.(%)	5184 (49.9)	39 (60,9)		4 (44.4)	2 (66.6)	1 (50)	6 (75)	8 (66.6)	5 (55.5)	12 (60)	1 (100)
median age - yr (range)	62 (0-99)	70 (12-88)		63 (26-77)	76 (37-88)	27 (26-28)	70.5 (52-83)	69.5 (40-78)	65 (26-83)	74 (25-88)	12
median ECLIA (COI) (IQR)	0.0781 (0.0753-0.0818)	0.084 (0.076-2.39)		33 (29.7-58.4)	4.46 (4-61.7)	31.3 (24.3-38.3)	0.07 (0.07-0.07)	1.72 (1.28-2.1)	0.07(0.07-0.08)	0.07 (0.07-0.08)	1.62
median CLEIA N (SU/ml) (IQR)	0.1 (0.14-0.29)	19 (1.5-71)		158 (123-196)	61.7 (49-65.5)	14.1 (12.1-16.2)	76.4 (62.1-104)	1.32 (0.5-2.81)	27.7 (23.8-60.8)	1.36 (0.59-6.39)	ND
median CLEIA S (SU/ml) (IQR)	0.28 (0.14-0.63)	47 (0.68-83)		152 (64-400)	29 (15.2-31.1)	53 (47.4-58.6)	361 (241-647)	0.31 (0.2-0.59)	0.24 (0.2-0.36)	52 (46.9-70)	ND
IC positive - no.(%)	22 (0.21)	22 (34.3)		9 (100)	2 (66.6)	1 (50)	0 (0)	2 (16.6)	7 (77.7)	1 (5)	0 (0)
Neutralization activity positive - no.(%)	16 (0.15)	16 (25%)		9 (100)	2 (66.6)	2 (100)	0 (0)	3 (25)	0 (0)	0 (0)	0 (0)
median Neutralization antibody titer (IQR)	ND	< 2 (<2-3)		64 (64-128)	8 (<2 - 64)	10 (7-13)	< 2	< 2	< 2	< 2	< 2

» Back to article page

Table 4. Results of the Neutralization Activity Titer and IC Test in 64 Individual Cases Classified Based on the Patterns of ECLIA, CLEIA-N and CLEIA-S.

From: Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan

	Both positive (N=14)									Either positive (N=50)
ECLIA	+			+			+			－			+			－			－			+
CLEIA-N	+			+			－			+			－			+			－			ND
CLEIA-S	+			－			+			+			－			－			+			ND
	(N=9)	NAb titer	IC	(N=3)	NAb titer	IC	(N=2)	NAb titer	IC	(N=8)	NAb titer	IC	(N=12)	NAb titer	IC	(N=9)	NAb titer	IC	(N=20)	NAb titer	IC	(N=1)	NAb titer	IC
	NI-4	64	+	X-2	64	+	HE-1	16	+	X-5	<2	－	NI-9	<2	－	AM-11	<2	－	AM-1	<2	－	CH-1	<2	－
	NI-5	128	+	X-6	<2	－	HE-4	4	－	X-9	<2	－	Ko-4	<2	－	HE-2	<2	+	AM-2	<2	－
	NI-7	64	+	HE-8	8	+				X-10	<2	－	Ko-10	4	+	HE-5	<2	+	AM-4	<2	－
	Ko-5	64	+							Ko-2	<2	－	Ko-11	<2	－	X-1	<2	－	AM-8	<2	－
	X-3	256	+							Ko-8	<2	－	Ko-15	<2	－	X-4	<2	+	AM-10	<2	－
	X-7	32	+							Ko-9	<2	－	X-12	8	－	X-8	<2	+	AM-12	<2	－
	AM-3	128	+							NI-1	<2	－	X-13	<2	－	X-15	<2	+	AM-13	<2	－
	AM-7	32	+							Ko-3	<2	－	X-14	8	－	X-2	<2	+	HE-6	<2	－
	AM-9	64	+										HE-3	8	－	NI-6	<2	+	HE-7	<2	－
													AM-5	<2	－				X-11	<2	+
													AM-6	<2	－				Ko-1	<2	－
													AM-14	<2	－				Ko-3	<2	－
																			Ko-6	<2	－
																			Ko-7	<2	－
																			Ko-12	<2	－
																			Ko-13	<2	－
																			Ko-14	<2	－
																			Ko-16	<2	－
																			NI-8	<2	－
																			NI-10	<2	－

» Back to article page